Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 151

1.

Phase 2b Controlled Trial of M72/AS01E Vaccine to Prevent Tuberculosis.

Van Der Meeren O, Hatherill M, Nduba V, Wilkinson RJ, Muyoyeta M, Van Brakel E, Ayles HM, Henostroza G, Thienemann F, Scriba TJ, Diacon A, Blatner GL, Demoitié MA, Tameris M, Malahleha M, Innes JC, Hellström E, Martinson N, Singh T, Akite EJ, Khatoon Azam A, Bollaerts A, Ginsberg AM, Evans TG, Gillard P, Tait DR.

N Engl J Med. 2018 Sep 25. doi: 10.1056/NEJMoa1803484. [Epub ahead of print]

2.

C-Tb skin test to diagnose Mycobacterium tuberculosis infection in children and HIV-infected adults: A phase 3 trial.

Aggerbeck H, Ruhwald M, Hoff ST, Borregaard B, Hellstrom E, Malahleha M, Siebert M, Gani M, Seopela V, Diacon A, Lourens M, Andersen P, Dheda K.

PLoS One. 2018 Sep 24;13(9):e0204554. doi: 10.1371/journal.pone.0204554. eCollection 2018.

3.

Droplets, dust and guinea pigs: an historical review of tuberculosis transmission research, 1878-1940.

Donald PR, Diacon AH, Lange C, Demers AM, von Groote-Biddlingmeier F, Nardell E.

Int J Tuberc Lung Dis. 2018 Sep 1;22(9):972-982. doi: 10.5588/ijtld.18.0173.

PMID:
30092861
4.

Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis.

Peloquin CA, Phillips PPJ, Mitnick CD, Eisenach K, Patientia RF, Lecca L, Gotuzzo E, Gandhi NR, Butler D, Diacon AH, Martel B, Santillan J, Hunt KR, Vargas D, von Groote-Bidlingmaier F, Seas C, Dianis N, Moreno-Martinez A, Kaur P, Horsburgh CR Jr.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e00770-18. doi: 10.1128/AAC.00770-18. Print 2018 Oct.

PMID:
30012767
5.

Toxicity associated with tuberculosis chemotherapy in the REMoxTB study.

Tweed CD, Crook AM, Amukoye EI, Dawson R, Diacon AH, Hanekom M, McHugh TD, Mendel CM, Meredith SK, Murphy ME, Murthy SE, Nunn AJ, Phillips PPJ, Singh KP, Spigelman M, Wills GH, Gillespie SH.

BMC Infect Dis. 2018 Jul 11;18(1):317. doi: 10.1186/s12879-018-3230-6.

6.

Relative bioavailability of bedaquiline tablets suspended in water: Implications for dosing in children.

Svensson EM, du Bois J, Kitshoff R, de Jager VR, Wiesner L, Norman J, Nachman S, Smith B, Diacon AH, Hesseling AC, Garcia-Prats AJ.

Br J Clin Pharmacol. 2018 Jun 27. doi: 10.1111/bcp.13696. [Epub ahead of print]

7.

The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis.

Svensson EM, Svensson RJ, Te Brake LHM, Boeree MJ, Heinrich N, Konsten S, Churchyard G, Dawson R, Diacon AH, Kibiki GS, Minja LT, Ntingiya NE, Sanne I, Gillespie SH, Hoelscher M, Phillips PPJ, Simonsson USH, Aarnoutse R.

Clin Infect Dis. 2018 Jun 18;67(1):34-41. doi: 10.1093/cid/ciy026.

8.

Perspectives for personalized therapy for patients with multidrug-resistant tuberculosis.

Lange C, Alghamdi WA, Al-Shaer MH, Brighenti S, Diacon AH, DiNardo AR, Grobbel HP, Gröschel MI, von Groote-Bidlingmaier F, Hauptmann M, Heyckendorf J, Köhler N, Kohl TA, Merker M, Niemann S, Peloquin CA, Reimann M, Schaible UE, Schaub D, Schleusener V, Thye T, Schön T.

J Intern Med. 2018 May 28. doi: 10.1111/joim.12780. [Epub ahead of print]

PMID:
29806961
9.

Greater Early Bactericidal Activity at Higher Rifampicin Doses Revealed by Modeling and Clinical Trial Simulations.

Svensson RJ, Svensson EM, Aarnoutse RE, Diacon AH, Dawson R, Gillespie SH, Moodley M, Boeree MJ, Simonsson USH.

J Infect Dis. 2018 Aug 14;218(6):991-999. doi: 10.1093/infdis/jiy242.

PMID:
29718390
10.

Pleural tuberculosis: A concise clinical review.

Shaw JA, Irusen EM, Diacon AH, Koegelenberg CF.

Clin Respir J. 2018 May;12(5):1779-1786. doi: 10.1111/crj.12900.

PMID:
29660258
11.

Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study.

Tweed CD, Wills GH, Crook AM, Dawson R, Diacon AH, Louw CE, McHugh TD, Mendel C, Meredith S, Mohapi L, Murphy ME, Murray S, Murthy S, Nunn AJ, Phillips PPJ, Singh K, Spigelman M, Gillespie SH.

BMC Med. 2018 Mar 28;16(1):46. doi: 10.1186/s12916-018-1033-7.

12.

Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trial.

Chen RY, Via LE, Dodd LE, Walzl G, Malherbe ST, Loxton AG, Dawson R, Wilkinson RJ, Thienemann F, Tameris M, Hatherill M, Diacon AH, Liu X, Xing J, Jin X, Ma Z, Pan S, Zhang G, Gao Q, Jiang Q, Zhu H, Liang L, Duan H, Song T, Alland D, Tartakovsky M, Rosenthal A, Whalen C, Duvenhage M, Cai Y, Goldfeder LC, Arora K, Smith B, Winter J, Barry Iii CE; Predict TB Study Group.

Gates Open Res. 2017 Nov 6;1:9. doi: 10.12688/gatesopenres.12750.1.

13.

Erratum for Alsultan et al., "Population Pharmacokinetics of AZD-5847 in Adults with Pulmonary Tuberculosis".

Alsultan A, Furin JJ, Du Bois J, van Brakel E, Chheng P, Venter A, Thiel B, Debanne SA, Boom WH, Diacon AH, Johnson JL, Peloquin CA.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e02229-17. doi: 10.1128/AAC.02229-17. Print 2018 Jan. No abstract available.

14.

An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial.

Bouton TC, Phillips PPJ, Mitnick CD, Peloquin CA, Eisenach K, Patientia RF, Lecca L, Gotuzzo E, Gandhi NR, Butler D, Diacon AH, Martel B, Santillan J, Hunt KR, Vargas D, von Groote-Bidlingmaier F, Seas C, Dianis N, Moreno-Martinez A, Horsburgh CR Jr.

Trials. 2017 Nov 25;18(1):563. doi: 10.1186/s13063-017-2292-x.

15.

Supported Cu0 nanoparticles catalyst for controlled radical polymerization reaction and block-copolymer synthesis.

Diacon A, Rusen E, Mocanu A, Nistor LC.

Sci Rep. 2017 Sep 4;7(1):10345. doi: 10.1038/s41598-017-10760-w.

16.

Population Pharmacokinetics of AZD-5847 in Adults with Pulmonary Tuberculosis.

Alsultan A, Furin JJ, Du Bois J, van Brakel E, Chheng P, Venter A, Thiel B, Debanne SA, Boom WH, Diacon AH, Johnson JL, Peloquin CA.

Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e01066-17. doi: 10.1128/AAC.01066-17. Print 2017 Oct. Erratum in: Antimicrob Agents Chemother. 2017 Dec 21;62(1):.

17.

A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses.

Svensson RJ, Aarnoutse RE, Diacon AH, Dawson R, Gillespie SH, Boeree MJ, Simonsson USH.

Clin Pharmacol Ther. 2018 Apr;103(4):674-683. doi: 10.1002/cpt.778. Epub 2017 Aug 7.

18.

Pulmonary TB: varying radiological presentations in individuals with HIV in Soweto, South Africa.

Kistan J, Laher F, Otwombe K, Panchia R, Mawaka N, Lebina L, Diacon A, Kana B, Martinson N.

Trans R Soc Trop Med Hyg. 2017 Mar 1;111(3):132-136. doi: 10.1093/trstmh/trx028.

19.

Triplicate Sputum Cultures for Efficacy Evaluation of Novel Antituberculosis Regimens.

Diacon AH, van Brakel E, Lounis N, Meyvisch P, Van Baelen B, De Marez T, Jenkins E, Dannemann B.

Am J Respir Crit Care Med. 2017 Dec 15;196(12):1612-1615. doi: 10.1164/rccm.201704-0796LE. No abstract available.

PMID:
28448721
20.

Acquisition of Rifampin Resistance in Pulmonary Tuberculosis.

Kayigire XA, Friedrich SO, van der Merwe L, Diacon AH.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e02220-16. doi: 10.1128/AAC.02220-16. Print 2017 Apr.

21.

Combating drug-resistant tuberculosis: the unexpected benefits of bedaquiline.

Furin J, Diacon AH, Andries K.

Int J Tuberc Lung Dis. 2017 Jan 1;21(1):4-5. doi: 10.5588/ijtld.16.0768. No abstract available.

PMID:
28157457
22.

Time Trends in Sputum Mycobacterial Load and Two-Day Bactericidal Activity of Isoniazid-Containing Antituberculosis Therapies.

De Jager V, van der Merwe L, Venter A, Donald PR, Diacon AH.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e02088-16. doi: 10.1128/AAC.02088-16. Print 2017 Apr.

23.

High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.

Boeree MJ, Heinrich N, Aarnoutse R, Diacon AH, Dawson R, Rehal S, Kibiki GS, Churchyard G, Sanne I, Ntinginya NE, Minja LT, Hunt RD, Charalambous S, Hanekom M, Semvua HH, Mpagama SG, Manyama C, Mtafya B, Reither K, Wallis RS, Venter A, Narunsky K, Mekota A, Henne S, Colbers A, van Balen GP, Gillespie SH, Phillips PPJ, Hoelscher M; PanACEA consortium.

Lancet Infect Dis. 2017 Jan;17(1):39-49. doi: 10.1016/S1473-3099(16)30274-2. Epub 2016 Oct 26.

24.

Serial measurements of transrenal mycobacterial DNA as indicators of the early bactericidal activity (EBA) of antituberculosis drugs.

Heyckendorf J, Labugger I, van der Merwe L, Garcia-Basteiro AL, Diacon AH, Lange C.

Tuberculosis (Edinb). 2017 Jan;102:31-33. doi: 10.1016/j.tube.2016.10.005. Epub 2016 Oct 27. No abstract available.

PMID:
28061950
25.

More on Treatment Outcomes in Multidrug-Resistant Tuberculosis.

Diacon AH, Van Baelen B, Theeuwes M.

N Engl J Med. 2016 Dec 29;375(26):2609-10. No abstract available.

PMID:
28032964
26.

Propidium monoazide and Xpert MTB/RIF to quantify Mycobacterium tuberculosis cells.

Kayigire XA, Friedrich SO, Karinja MN, van der Merwe L, Martinson NA, Diacon AH.

Tuberculosis (Edinb). 2016 Dec;101:79-84. doi: 10.1016/j.tube.2016.08.006. Epub 2016 Sep 4.

PMID:
27865403
27.

Novel facile method for obtaining CdSe/polyaniline/C60 composite materials.

Rusen E, Diacon A, Mocanu A, Nistor LC.

Sci Rep. 2016 Aug 30;6:32237. doi: 10.1038/srep32237.

28.

Early Bactericidal Activity of AZD5847 in Patients with Pulmonary Tuberculosis.

Furin JJ, Du Bois J, van Brakel E, Chheng P, Venter A, Peloquin CA, Alsultan A, Thiel BA, Debanne SM, Boom WH, Diacon AH, Johnson JL.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6591-6599. doi: 10.1128/AAC.01163-16. Print 2016 Nov.

29.

β-Lactams against Tuberculosis--New Trick for an Old Dog?

Diacon AH, van der Merwe L, Barnard M, von Groote-Bidlingmaier F, Lange C, García-Basteiro AL, Sevene E, Ballell L, Barros-Aguirre D.

N Engl J Med. 2016 Jul 28;375(4):393-4. doi: 10.1056/NEJMc1513236. Epub 2016 Jul 13. No abstract available.

30.

Ultrathin bronchoscopy for solitary pulmonary lesions in a region endemic for tuberculosis: a randomised pilot trial.

Franzen D, Diacon AH, Freitag L, Schubert PT, Wright CA, Schuurmans MM.

BMC Pulm Med. 2016 Apr 27;16(1):62. doi: 10.1186/s12890-016-0225-1.

31.

Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults.

Furin J, Alirol E, Allen E, Fielding K, Merle C, Abubakar I, Andersen J, Davies G, Dheda K, Diacon A, Dooley KE, Dravnice G, Eisenach K, Everitt D, Ferstenberg D, Goolam-Mahomed A, Grobusch MP, Gupta R, Harausz E, Harrington M, Horsburgh CR, Lienhardt C, McNeeley D, Mitnick CD, Nachman S, Nahid P, Nunn AJ, Phillips P, Rodriguez C, Shah S, Wells C, Thomas-Nyang'wa B, du Cros P.

Int J Tuberc Lung Dis. 2016 Mar;20(3):290-4. doi: 10.5588/ijtld.15.0490.

32.

A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP).

Phillips PP, Dooley KE, Gillespie SH, Heinrich N, Stout JE, Nahid P, Diacon AH, Aarnoutse RE, Kibiki GS, Boeree MJ, Hoelscher M.

BMC Med. 2016 Mar 23;14:51. doi: 10.1186/s12916-016-0597-3.

33.

Direct Susceptibility Testing of Mycobacterium tuberculosis for Pyrazinamide by Use of the Bactec MGIT 960 System.

Demers AM, Venter A, Friedrich SO, Rojas-Ponce G, Mapamba D, Jugheli L, Sasamalo M, Almeida D, Dorasamy A, Jentsch U, Gibson M, Everitt D, Eisenach KD, Diacon AH.

J Clin Microbiol. 2016 May;54(5):1276-81. doi: 10.1128/JCM.03162-15. Epub 2016 Feb 24.

34.

Erratum to: Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials.

Phillips PP, Mendel CM, Burger DA, Crook AM, Nunn AJ, Dawson R, Diacon AH, Gillespie SH.

BMC Med. 2016 Feb 23;14:36. doi: 10.1186/s12916-016-0585-7. No abstract available.

35.

Direct comparison of liquid-based and smear-based cytology with and without rapid on-site evaluation for fine needle aspirates of thoracic tumors.

Mfokazi A, Wright CA, Louw M, Von Groote-Bidlingmaier F, Schubert PT, Koegelenberg CF, Diacon AH.

Diagn Cytopathol. 2016 May;44(5):363-8. doi: 10.1002/dc.23447. Epub 2016 Feb 8.

PMID:
26853711
36.

Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials.

Phillips PP, Mendel CM, Burger DA, Crook AM, Nunn AJ, Dawson R, Diacon AH, Gillespie SH.

BMC Med. 2016 Feb 4;14:19. doi: 10.1186/s12916-016-0565-y. Erratum in: BMC Med. 2016;14:36. Crook, Angela [corrected to Crook, Angela M].

37.

Stair Climbing Test Streamlines the Evaluation of Nonmalignant Lung Resection Candidates.

Bernasconi M, Diacon AH, Koegelenberg CF.

Respiration. 2016;91(1):87-8. doi: 10.1159/000442889. Epub 2015 Dec 17. No abstract available.

38.

Recruitment challenges for clinical trials with novel regimens for drug-resistant tuberculosis.

Siwendu S, Mitchell M, Diacon AH, von Groote-Bidlingmaier F.

Eur Respir J. 2016 Feb;47(2):670-2. doi: 10.1183/13993003.01330-2015. Epub 2015 Dec 2. No abstract available.

39.

Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.

Pym AS, Diacon AH, Tang SJ, Conradie F, Danilovits M, Chuchottaworn C, Vasilyeva I, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, Van Baelen B, van Heeswijk RP, Dannemann B; TMC207-C209 Study Group.

Eur Respir J. 2016 Feb;47(2):564-74. doi: 10.1183/13993003.00724-2015. Epub 2015 Dec 2.

40.

Simultaneous staining of sputum smears for acid-fast and lipid-containing Myobacterium tuberculosis can enhance the clinical evaluation of antituberculosis treatments.

Kayigire XA, Friedrich SO, van der Merwe L, Donald PR, Diacon AH.

Tuberculosis (Edinb). 2015 Dec;95(6):770-779. doi: 10.1016/j.tube.2015.08.001. Epub 2015 Aug 13.

PMID:
26318558
41.

A Step toward an Optimized Rifampin Dose Completed.

Boeree MJ, Diacon AH, Dawson R, Narunsky K, du Bois J, Venter A, Phillips PP, Gillespie SH, McHugh TD, Hoelscher M, Heinrich N, Rehal S, van Soolingen D, van Ingen J, Magis-Escurra C, Burger D, Plemper van Balen G, Aarnoutse RE.

Am J Respir Crit Care Med. 2015 Aug 15;192(4):525-6. doi: 10.1164/rccm.201506-1061LE. No abstract available.

PMID:
26278799
42.

Para-aminosalicylic acid: the return of an old friend.

Donald PR, Diacon AH.

Lancet Infect Dis. 2015 Sep;15(9):1091-1099. doi: 10.1016/S1473-3099(15)00263-7. Epub 2015 Aug 12. Review.

PMID:
26277036
43.

Tuberculous pleural effusions: advances and controversies.

Vorster MJ, Allwood BW, Diacon AH, Koegelenberg CF.

J Thorac Dis. 2015 Jun;7(6):981-91. doi: 10.3978/j.issn.2072-1439.2015.02.18. Review.

44.

The utility of ultrasound-guided thoracentesis and pleural biopsy in undiagnosed pleural exudates.

Koegelenberg CF, Irusen EM, von Groote-Bidlingmaier F, Bruwer JW, Batubara EM, Diacon AH.

Thorax. 2015 Oct;70(10):995-7. doi: 10.1136/thoraxjnl-2014-206567. Epub 2015 May 21.

PMID:
25997433
45.

Combinations of β-Lactam Antibiotics Currently in Clinical Trials Are Efficacious in a DHP-I-Deficient Mouse Model of Tuberculosis Infection.

Rullas J, Dhar N, McKinney JD, García-Pérez A, Lelievre J, Diacon AH, Hugonnet JE, Arthur M, Angulo-Barturen I, Barros-Aguirre D, Ballell L.

Antimicrob Agents Chemother. 2015 Aug;59(8):4997-9. doi: 10.1128/AAC.01063-15. Epub 2015 May 18.

46.

N-acetyltransferase genotypes and the pharmacokinetics and tolerability of para-aminosalicylic acid in patients with drug-resistant pulmonary tuberculosis.

Sy SK, de Kock L, Diacon AH, Werely CJ, Xia H, Rosenkranz B, van der Merwe L, Donald PR.

Antimicrob Agents Chemother. 2015 Jul;59(7):4129-38. doi: 10.1128/AAC.04049-14. Epub 2015 May 11.

47.

Mediastinal granulomatous lymphadenitis in a population at risk for HIV and tuberculosis.

De Wet DR, Wright CA, Schubert PT, Koegelenberg CF, Louw M, Diacon AH.

Diagn Cytopathol. 2015 Sep;43(9):696-700. doi: 10.1002/dc.23280. Epub 2015 May 4.

PMID:
25939898
48.

Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.

Dawson R, Diacon AH, Everitt D, van Niekerk C, Donald PR, Burger DA, Schall R, Spigelman M, Conradie A, Eisenach K, Venter A, Ive P, Page-Shipp L, Variava E, Reither K, Ntinginya NE, Pym A, von Groote-Bidlingmaier F, Mendel CM.

Lancet. 2015 May 2;385(9979):1738-1747. doi: 10.1016/S0140-6736(14)62002-X. Epub 2015 Mar 18.

PMID:
25795076
49.

A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.

Boeree MJ, Diacon AH, Dawson R, Narunsky K, du Bois J, Venter A, Phillips PP, Gillespie SH, McHugh TD, Hoelscher M, Heinrich N, Rehal S, van Soolingen D, van Ingen J, Magis-Escurra C, Burger D, Plemper van Balen G, Aarnoutse RE; PanACEA Consortium.

Am J Respir Crit Care Med. 2015 May 1;191(9):1058-65. doi: 10.1164/rccm.201407-1264OC.

PMID:
25654354
50.

Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients.

Heinrich N, Dawson R, du Bois J, Narunsky K, Horwith G, Phipps AJ, Nacy CA, Aarnoutse RE, Boeree MJ, Gillespie SH, Venter A, Henne S, Rachow A, Phillips PP, Hoelscher M, Diacon AH; Pan African Consortium for the Evaluation of Antituberculosis Antibiotics (PanACEA); Pan African Consortium for the Evaluation of Antituberculosis Antibiotics PanACEA.

J Antimicrob Chemother. 2015 May;70(5):1558-66. doi: 10.1093/jac/dku553. Epub 2015 Jan 27.

PMID:
25630641

Supplemental Content

Loading ...
Support Center